---
title: "Azithromycin MDA and antimicrobial resistance in Mali: LAKANA trial sub-study results"
id: "plos-medicine-0-analysis-of-antimicrobial-resistance-in-the-lakana-trial-of-azithromycin"
canonical_url: "https://medichelpline.com/clinical-feed/plos-medicine-0-analysis-of-antimicrobial-resistance-in-the-lakana-trial-of-azithromycin"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "PLOS Medicine"
source_url: "https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005296"
published_at: "2026-11-13T14:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Azithromycin MDA and antimicrobial resistance in Mali: LAKANA trial sub-study results
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/plos-medicine-0-analysis-of-antimicrobial-resistance-in-the-lakana-trial-of-azithromycin
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** PLOS Medicine
- **Source URL:** [Original Journal Publication](https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005296)
- **Published At:** 2026-11-13T14:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
- The LAKANA trial was a cluster-randomized, placebo-controlled three-arm study in Mali assessing mass drug administration (MDA) of **azithromycin** to infants aged 1–11 months; this sub-study measured antimicrobial resistance (AMR) in sentinel bacteria. - Repeated cross-sectional nasopharyngeal and rectal swabs were collected at baseline and at 12, 24, and 36 months from children aged 4–14 months and from untreated contacts aged 49–59 months across 59 villages; all samples at primary time points were analyzed. - Sentinel organisms were **Streptococcus pneumoniae** (from nasopharyngeal swabs) and **Escherichia coli** (from rectal swabs); phenotypic resistance testing used disk diffusion and E-test MIC determinations following EUCAST guidelines (with specified exceptions for ciprofloxacin and azithromycin in E. coli). - The prespecified primary noninferiority comparison assessed macrolide resistance prevalence at 36 months in younger children and at 24 months in older contacts, with a +10 percentage-point noninferiority margin. - At 36 months, macrolide resistance prevalences in infants for **S. pneumoniae** were reported as 13.4% (placebo), 14.5% (twice-yearly azithromycin), and 17.2% (quarterly azithromycin); for **E. coli** the figures were 5.1%, 6.4%, and 9.1%, respectively. - Differences between placebo and twice-yearly arms at 36 months were small and met the noninferiority margin for both organisms; quarterly dosing could not exclude a modest increase in macrolide resistance for **S. pneumoniae** and **E. coli**. - Among untreated older children sampled at 24 months, investigators observed no marked intergroup differences in macrolide resistance at baseline or at 24 months. - The sub-study found no consistent increase in resistance to nonmacrolide antibiotic classes. - The authors noted the study may have been underpowered to detect small increases in macrolide resistance in the quarterly azithromycin arm and cautioned against extrapolating results to programs treating wider age ranges or larger population proportions. - The data support restriction of MDA to infants aged 1–11 months in this setting, with the explicit recommendation that any MDA program include continuous AMR surveillance, especially if expanded to broader age groups or higher coverage.
## Clinical Analysis & Structured Key Points
Analysis of antimicrobial resistance in the LAKANA trial of azithromycin administration in Mali: A sub-study of a cluster randomized clinical trial | PLOS Medicine Article Authors Metrics Comments Media Coverage Reader Comments Figures ? This is an uncorrected proof. Figures Abstract Background Mass azithromycin administration has been used to reduce under-five mortality in sub-Saharan Africa, but concerns remain about its potential impact on antimicrobial resistance (AMR). Methods and findings The Large-scale Assessment of the Key health-promoting Activities of two New mass drug administration regiments with Azithromycin (LAKANA) trial was a cluster-randomized, placebo-controlled trial conducted in Mali, enrolling infants aged 1−11 months randomized to placebo, twice-yearly azithromycin, or quarterly azithromycin for 2 years. The trial did not find any mortality benefit amongst treated children. The current analysis is a sub-study of the parent trial examining AMR outcomes. Repeated cross-sectional nasopharyngeal and rectal swabs were collected from children aged 4–14-months in villages randomized to placebo, twice-yearly or quarterly azithromycin, and from untreated contacts aged 49–59-months at baseline, 12-, 24-, and 36-months post-village enrollment across 59 LAKANA trial villages. Phenotypic resistance to macrolide and nonmacrolide antibiotics was assessed in Streptococcus pneumoniae ( S. pneumoniae ) and Escherichia coli ( E. coli ) isolates using disk diffusion or E-tests. The primary noninferiority analysis evaluated macrolide resistance prevalence at 36-months among younger children and at 24-months among older contacts, with predefined margin of +10 percentage points. A total of 5,025 nasopharyngeal and 5,021 rectal samples were analyzed. At baseline, among 4–14-month-old children, macrolide resistance in S. pneumoniae was 16.6%, 15.5%, and 11.1% in the placebo, twice-yearly and quarterly azithromycin groups, respectively, and 5.0%, 5.0%, and 0.0% in E. coli . At 36-months, corresponding prevalences were 13.4%, 14.5%, and 17.2% for S. pneumoniae , and 5.1%, 6.4%, and 9.1% for E. coli . The difference between placebo and twice-yearly groups was 1.0% (95% CI [−4.7, 6.8]) for S. pneumoniae and 1.3% (95% CI [−2.4, 4.9]) for E. coli ; corresponding differences for quarterly azithromycin group was 3.8% (95% CI [−3.3, 10.9]) for S. pneumoniae and 4.0% (95% CI [−0.7, 8.7]) for E. coli. Among untreated older children, there were no marked inter-group differences in macrolide resistance either at baseline or at 24-months. The study may not have been large enough to detect a small increase in macrolide resistance in S. pneumoniae among young children in villages that received quarterly azithromycin. Conclusions Twice-yearly azithromycin administration to 1–11-month-old infants for 2 years in Mali did not increase macrolide resistance in treated children or untreated contacts and met the predefined noninferiority margin in tested isolates. Quarterly administration, however, cannot exclude a modest dose-dependent increase of macrolide resistance in S. pneumoniae and E. coli . Author summary Why was this study done? Mass drug administration (MDA) of azithromycin can reduce childhood mortality in some sub-Saharan African settings, but its effects on antimicrobial resistance (AMR) at the population level remain uncertain. The LAKANA trial in Mali found no reduction in childhood mortality with twice-yearly or quarterly azithromycin administration. However, a lack of mortality benefit does not preclude effects on AMR, including potential effects beyond treated children. This study assessed the population-level effects of azithromycin MDA on macrolide and nonmacrolide antibiotic resistance in treated infants and examined whether resistance spilled over to untreated children. What did the researchers do and find? As a sub-study of the large, population-based LAKANA trial in Mali, we collected cross-sectional nasopharyngeal and rectal samples from children aged 4–14 months who received twice-yearly azithromycin, quarterly azithromycin, or placebo, and from untreated children aged 49–59 months, at baseline and at 12-, 24-, and 36-months after village enrollment. We measured phenotypic resistance to macrolide and nonmacrolide antibiotics in Streptococcus pneumoniae ( S. pneumoniae ) and Escherichia coli ( E. coli ) isolates. Twice-yearly azithromycin did not increase macrolide resistance in treated infants after 36 months, and there was no evidence of increased resistance among untreated older children. For quarterly azithromycin, a modest dose-dependent increase in macrolide resistance in S. pneumoniae and E. coli could not be excluded. There was no consistent increase in resistance to nonmacrolide antibiotics . What do these findings mean? In this setting, restricting mass azithromycin administration to infants aged 1–11 months for 2 years did not appear to increase AMR at the population level or result in detectable resistance spillover to untreated children. These findings cannot be extrapolated to programmes treating a larger proportion of the population, such as children aged 1–59 months, where greater antibiotic exposure could have different effects on AMR. Future mass azithromycin programmes should be accompanied by continuous AMR surveillance to determine whether regimens that provide mortality benefits can do so while limiting the emergence and spread of AMR, particularly when extending treatment to broader age groups, using different dosing regimens, or implementing MDA in settings with different baseline resistance levels. The study may not have been large enough to detect a small increase in macrolide resistance in S. pneumoniae among young children in villages that received 4 doses of azithromycin per year. Citation: Juma J, Luoma J, Traore A, Sangare A, Bouare O, Cheick Haidara F, et al. (2026) Analysis of antimicrobial resistance in the LAKANA trial of azithromycin administration in Mali: A sub-study of a cluster randomized clinical trial. PLoS Med 23(11): e1005296. https://doi.org/10.1371/journal.pmed.1005296 Academic Editor: Lorenz von Seidlein, Mahidol-Oxford Tropical Medicine Research Unit, THAILAND Received: May 19, 2026; Accepted: October 14, 2026; Published: November 13, 2026 Copyright: © 2026 Juma et al. This is an open access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Data Availability: The data from this study have been deposited in Zenodo (LAKANA AMR HIPAA deidentifying data. https://doi.org/10.5281/zenodo.20523591 ). Code used in this study can be found in the Supporting information . Because open data sharing was not included in the study information sheet at the time of data collection, access to these datasets is restricted. Data will be made available to users who submit a written request outlining their proposed use and providing a justification and data use plan. Access requests should be submitted to the LAKANA Trial Principal Investigators at lakana.psg@lists.tuni.fi . Funding: This work was supported by the Gates Foundation grants (OPP1210821, INV-005877, and INV-003354) https://www.gatesfoundation.org/ . The fundings were all obtained by PA on behalf of the research team and administered through Tampere University. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Competing interests: The authors have declared that no competing interests exist. Abbreviations: AMR, antimicrobial resistance; AST, antimicrobial susceptibility testing; CHAT, Child Health with Azithromycin Trial; CI, confidence interval; CV, coefficient of variation; EUCAST, European Committee on Antibiotic Susceptibility Testing; FG, Fay-Graubard; ICC, intraclass correlation coefficient; IRB, Institutional Review Board; MDA, Mass drug administration; MICs, minimum inhibitory concentrations; NPS, nasopharyngeal swab; SE, standard errors; STGG, skim milk, tryptone, glucose, and glycerin; TANA, Trachoma Amelioration in Northern Amhara; WHO, World Health Organization. Introduction Despite significant global progress, 4.8 million children under the age of five died in 2023, with mortality rates remaining high in sub-Saharan Africa [ 1 ]. Mass drug administration (MDA) of azithromycin to children aged 1–59 months has been shown to reduce childhood mortality in some sub-Saharan African settings [ 2 , 3 ]. However, it has also been linked to rising antimicrobial resistance (AMR) [ 4 , 5 ]. Consequently, the World Health Organization (WHO) has recommended azithromycin administration to children aged 1–11-month in settings with high under-five mortality rates, while simultaneously calling for continuous monitoring of AMR [ 6 ]. Although azithromycin mass administration has shown promise in specific contexts, variations in the age groups treated, drug dosage and the use of microbial surveillance methods across studies have limited comparability. As a result, concerns about its long-term impact on AMR remain central to evaluating this public health strategy. The Large-scale Assessment of the Key health-promoting Activities of two New mass drug administration regimens with Azithromycin (LAKANA) trial in Mali, evaluated the effects on mortality of mass administration of azithromycin twice-yearly and quarterly over two years in infants aged 1–11 months. The LAKANA trial showed no evidence of reduced mortality [ 7 ]. As mass administration of azithromycin represents large-scale antimicrobial exposure with potential consequences for resistance patterns in the treated population, investigation of AMR is important for understanding the broader public health implications of MDA strategies and informing future treatment recommendations, particularly in settings where resistant pathogens are prevalent. We examined whether phenotypic macrolide resistance among S. pneumoniae and E. coli isolates was noninferior in the intervention group compared with the placebo group at 36 months in children aged 4–14 months and at 24 months in children aged 49–59 months. We additionally characterized AMR to macrolide and nonmacrolide antibiotic classes through annual monitoring over 3 years in both age groups. Methods Study design and oversight LAKANA was a double-blinded, cluster-randomized, placebo-controlled, and three-arm trial with an adaptive design conducted in Mali. Villages were randomly assigned in a 3:4:2 ratio to receive placebo (control group), azithromycin two times a year (twice-yearly azithromycin group), or azithromycin four times a year (quarterly azithromycin group). Alongside the mortality study, 59 villages in the Kita region, considered nonurban, accessible, and safe by the local health authorities and research team, were selected for their proximity to the study headquarters and health facilities to serve as the secondary outcome sample. These villages were drawn from the larger pool of clusters participating in the mortality trial. Repeated cross-sectional samples were drawn to collect nasopharyngeal and rectal swabs at baseline, and at 12-, 24-, and 36-month post-village enrollment in the trial. Sentinel bacteria ( S. pneumoniae and E. coli ) were isolated and phenotypically tested for resistance to antibiotic classes. Changes in resistance to antibiotic classes were the pre-specified outcomes assessed at annual monitoring visits from April 2021 to July 2025. Further details of the methods can be found in the trial protocol, available with the full text of this article at NEJM.org , and were previously reported [ 8 ]. The Mali Institutional Review Board (IRB)—Comité d'Éthique de l’Université des Sciences, des Techniques et des Technologies de Bamako—provided ethics approval for LAKANA trial (IRB approval number: N2019/181/ CE/FMPOS/FAPH). The study was initially approved on 27 December 2019, with the most recent annual reapproval (IRB approval number: N2025/200/USTBB) granted on 13 October 2025. The researchers also received approval for the trial from the Ethics Committee of the Pirkanmaa Hospital District (R20028M). Independent expert committees advised the investigators on design and implementation, while a data and safety monitoring board monitored trial progress and safety. Pfizer provided all trial drugs but had no access to the trial data or group assignments. Permissions were granted by village leaders for the trial to be conducted in their villages. Oral consent, recorded as “yes” or “no” and documented with a digital signature on tablets, was obtained from household heads or authorized proxies before trial activities began, once at enrollment. Informed oral consent was obtained from at least one caregiver for treatment of infants and documented electronically on the tablets. Written informed consent from household representatives were obtained for nasopharyngeal and rectal swabs sample collection. This consent was documented electronically on the tablets and the signed paper copy of the informed consent form was given to the household representative for their records. Participants All infants aged 1–11 months and weighing at least 3.0 kg were eligible to receive azithromycin or placebo. Infants with known macrolide allergies, or severe illness requiring referral to health facilities were excluded. For the AMR sub-study sampling, participants included children aged 4–14-month and 49–59-month. The 4–14-month group ensured that all sampled children had received the preceding MDA ~3 months earlier. Children aged 49–59 months (untreated contacts) were chosen as they never received azithromycin MDA throughout the study. All children present in the village at the time of visit for sample collection were eligible to participate. Randomization and masking The randomization unit (cluster) was the village. Randomization was stratified according to cluster size (<100 infants or ≥100 infants) on the basis of national population estimates. Eighteen letters of the alphabet were randomly assigned to azithromycin or placebo, and combinations of these letters were used to allocate villages (clusters) in a 3:4:2 ratio to placebo, twice-yearly, and quarterly azithromycin treatment arms. The allocation was selected to ensure adequate statistical power for the primary mortality comparisons in the LAKANA trial [ 7 ]. Randomization occurred at public events. All the sub-study villages were randomized in a single event. Unmasked personnel included staff from Research Triangle Institute International, Pfizer, an external statistician, and the chair of the data and safety monitoring board. Study arm allocation was masked to participants, site staff, investigators, laboratory personnel, and the statistician who led the analysis. Azithromycin and placebo were similar in appearance, smell, and packaging to maintain masking. Intervention Infants 1–11 months of age were weighed, and data collectors administered oral azithromycin or placebo suspension using syringes under direct observation, at a single dose of 20 mg per kilogram of body weight at each visit. Sample collection Study nurses collected nasopharyngeal swab (NPS) and rectal swab samples from children aged 4–14 and 49–59 months (the latter being contacts who never received study drug) at a central place in each village at four time points. The baseline visit was conducted prior to any treatment distribution. The 12-month visit occurred ~1 year after enrollment, the 24-month visit about 3 months after the final round, and the 36-month visit ~1 year after the final round of intervention. A nasopharyngeal swab (503CS01, Copan Diagnostics) was inserted into one nostril to reach the nasopharynx and gently rotated 180°, then removed and placed in the vial containing skim milk, tryptone, glucose, and glycerin (STGG) media. One flocked rectal swab (520CS01, Copan Diagnostics) was inserted ~3 cm into the child’s anus and gently twisted at 180°, then removed and stored in the vial containing Cary-Blair media. A new pair of surgical gloves was worn for each participant. The samples were kept in cooler boxes at +4 °C in the field and transported within 24–48 hours to the main laboratory in Bamako, where a laboratory technician processed and stored them at −80 °C until analysis. Sample selection At the primary outcome time point (36-month visit for children aged 4–14-months and 24-month visit for children aged 49–59-months), all collected nasopharyngeal and rectal swab samples were analyzed without sample selection. For other timepoints, collected samples were selected from each village-age group (4–5-, 6–8-, 9–11, 12–14-, and 49–59-month) to achieve total ~600 children aged 4–14-months at baseline, 12-, and 24-month visits, and ~600 children aged 49–59-months at 12-, and 36-month visits. Participants were stratified by village and age group to obtain an equal number of children from each village-age group combination. For village-age groups that had a smaller number of children available than the target, all children were included. S. pneumoniae identification and antimicrobial susceptibility testing (AST) Stored STGG samples were thawed, vortexed, and 200 µL inoculated into 5 mL Todd Hewitt broth containing 0.5% yeast extract and 1 mL rabbit serum, then incubated at 37 °C for 4–6 hours. 20 µL aliquot was streaked onto sheep blood agar with an optochin disk (5 µg) and incubated at 35–37 °C in 5% CO 2 for 18–24 hours. Colonies showing alpha hemolysis and an inhibition zone ≥ 14 mm were identified as S. pneumoniae ; isolates with 6–13 mm zones were confirmed by bile solubility. Colonies for AST were randomly selected when multiple isolates were present in a culture. AST was determined according to European Committee on Antibiotic Susceptibility Testing (EUCAST) v12.0 breakpoint, except for ciprofloxacin, which followed British Society for Antimicrobial Chemotherapy guidelines (v14). Discs tested included erythromycin (15 µg), ampicillin (2 µg), ciprofloxacin (1 µg), co-trimoxazole (trimethoprim/sulfamethoxazole 1:19, 25 µg), oxacillin (1 µg), and vancomycin (5 µg). Erythromycin-susceptible isolates were considered azithromycin-susceptible; erythromycin-resistant isolates were further tested for azithromycin minimum inhibitory concentrations (MICs) by E-test (0.016–256 mg/L, bioMérieux). S. pneumoniae ATCC 49619 served as a quality control strain. E . coli identification and AST Stored Cary Blair rectal swab samples were thawed and streaked onto Coliform ChromoSelect Agar plates. After incubating the plates at 36 ± 1 °C for 18–24 hours, colonies displaying a dark blue to violet color were presumed to be E. coli and were sub-cultured onto TSA plates for purity and confirmed using indole spot test. Colonies for AST were randomly selected when multiple isolates were present in a culture. AST was performed using the disk diffusion method following EUCAST guidelines (v12.0) to determine zone diameters and MICs. Antibiotic discs (OXOID) included ampicillin (10 µg), ciprofloxacin (5 µg), co-trimoxazole (trimethoprim/sulfamethoxazole 1:19, 25 µg), ceftriaxone (30 µg), meropenem, and gentamicin (10 µg). Azithromycin resistance was assessed by E-test (0.016–256 mg/L, bioMérieux). As EUCAST does not provide breakpoints for azithromycin resistance in E. coli , MIC thresholds of ≥32 mg/L were used, based on previously published criteria [ 9 , 10 ]. MIC ≥ 16 mg/L was used for sensitivity analysis. E. coli ATCC 25922 served as a quality control strain. Outcomes Our prespeciﬁed primary outcome was the prevalence of phenotypic azithromycin (macrolide)-resistant S. pneumoniae and E. coli from isolates obtained from children aged 4–14 months at the 36-month visit and from children aged 49–59-months at the 24-month visit across the three study arms. Other outcomes included comparisons betw
## Related Clinical Research

- [Eritrea validated by WHO for elimination of trachoma as a public health problem](https://medichelpline.com/clinical-feed/who-0-4-eritrea-eliminates-trachoma-a-major-public-health-milestone.md)
- [Intrapartum oral azithromycin vs placebo for maternal infection in South East Asia](https://medichelpline.com/clinical-feed/pubmed-43050477.md) (DOI: 10.1371/journal.pone.0346359)
- [Pharyngeal Gonorrhea vs Urogenital Strains in Ugandan Men: AMR and Genomic Differences](https://medichelpline.com/clinical-feed/pubmed-42415364.md) (DOI: 10.1093/infdis/jiag353)
- [Multidrug-resistant Salmonella in Fruit Bats and Shared Water Sources in Bangladesh](https://medichelpline.com/clinical-feed/plos-one-22-ecology-and-epidemiology-of-multidrug-resistance-salmonella-in-fruit-bats-and.md)
- [Molecular typing and AMR determinants of Neisseria gonorrhoeae in Eastern Cape, South Africa](https://medichelpline.com/clinical-feed/medrxiv-18-molecular-typing-and-characterisation-of-antimicrobial-resistance-determinants.md)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.